1 MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.

2 sleep disordered breathing in patients with chronic kidney diseases: how far the problem?

3 Synthesis and biological evaluation of 2.4 nm thiolate-protected gold nanoparticles conjugated to Cetuximab for targeting glioblastoma cancer cells via the EGFR.

4 Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors.

5 Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents.

6 Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing.

7 Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.

8 EGFR signaling in colorectal cancer: a clinical perspective

9 EGFR signaling in colorectal cancer: a clinical perspective

10 EGFR signaling in colorectal cancer: a clinical perspective

11 New amide linked dimeric 1,2,3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors.

12 Synthesis and preclinical investigation of Tc-p-SCN-Bzl-DTPA-cetuximab for targeting EGFR using head and neck squamous cell carcinoma (HNSCC) xenografts.

13 Pyrazolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model.

14 KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program

15 Interleukin 1 beta and Matrix Metallopeptidase 3 Contribute to Development of EGFR-dependent Serrated Polyps in Mouse Cecum.

16 Icariin and icaritin stimulate the proliferation of SKBr3 cells through the GPER1-mediated modulation of the EGFR-MAPK signaling pathway.

17 Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.

18 EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer.

19 Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.

20 Correction: Kaempferol inhibits angiogenesis by suppressing hif-1α and vegfr2 activation via erk/p38 mapk and pi3k/akt/mtor signaling pathways in endothelial cells (Preventive Nutrition and Food Science (2017) 22: 4 (320-326)

21 Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.

22 Single-cell RNA-seq reveals RAD51AP1 as a potent mediator of EGFRvIII in human glioblastomas.

23 Decreased eGFR Is Associated With Ischemic Stroke in Patients With Dilated Cardiomyopathy.

24 Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.

25 The heart of a hibernator: EGFR and MAPK signaling in cardiac muscle during the hibernation of thirteen-lined ground squirrels, .

26 Compression after Impact Behaviour and Failure Analysis of Nanosilica-Toughened Thin Epoxy/GFRP Composite Laminates.

27 The Durability of an Organic-Inorganic Sol-Gel Interlayer in Al-GFRP-CFRP Laminates in a Saline Environment.

28 Fatigue behavior of concrete beams reinforced with glass- and carbon-fiber reinforced polymer (GFRP/CFRP) bars after exposure to elevated temperatures

29 Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors

30 Synthesis of Triazole-Substituted Quinazoline Hybrids for Anticancer Activity and a Lead Compound as the EGFR Blocker and ROS Inducer Agent

31 Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.

32 Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo[1,5-c]quinazolines as potential EGFR inhibitors.

33 Synthesis, molecular docking, and evaluation of novel bivalent pyrazolinyl-1,2,3-triazoles as potential VEGFR TK inhibitors and anti-cancer agents

34 ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.

35 EGFR signaling promotes β-cell proliferation and survivin expression during pregnancy.

36 Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.

37 Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells.

38 Ibrutinib potentiates anti-hepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma.

39 Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m and negative proteinuria.

40 Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA.

41 Dysregulation of FGFR signalling by a selective inhibitor reduces germ cell survival in human fetal gonads of both sexes and alters the somatic niche in fetal testes.

42 Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.

43 FGFR3 deficiency enhances CXCL12-dependent chemotaxis of macrophages via upregulating CXCR7 and aggravates joint destruction in mice.

44 Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.

45 Asporin enhances colorectal cancer metastasis through activating the EGFR/src/cortactin signaling pathway

46 Vascular Endothelial Growth Factor A and VEGFR-1 Change during Preimplantation in Heifers.

47 Investigation of mechanical properties of GFRP pipe production waste filled pvc matrix composites

48 Assessment of PDGFRβ promoter methylation in canine osteosarcoma using methylation-sensitive high-resolution melting analysis.

49 Behaviors of GFRP-steel bonded joints under cyclic loading after hygrothermal aging

50 Modal parameter identification of all-GFRP composite cable-stayed footbridge in Denmark

51 Corrigendum to ‘Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2’ [European journal of medicinal chemistry 158 (2018) 814–831](S0223523418308225)(10.1016/j.ejmech.2018.09.050)

52 Chatteringfree hybrid adaptive neuro-fuzzy inference system-particle swarm optimisation data fusion-based BG-level control.

53 Structural performance of concrete beams with micro-reinforcement strengthened with GFRP laminates under monotonic loading

54 Effects of RO27-3225 on neurogenesis, PDGFRβ cells and neuroinflammation after cerebral infarction.

55 Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles.

56 Prospective pediatric study comparing glomerular filtration rate estimates based on motion-robust dynamic contrast-enhanced magnetic resonance imaging and serum creatinine (eGFR) to Tc DTPA.

57 Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.

58 Correction to: EGFR signaling augments TLR4 cell surface expression and function in macrophages via regulation of Rab5a activation.

59 Suramin derivatives play an important role in blocking the interaction between FGF1 and FGFRD2 to inhibit cell proliferation

60 Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes

61 Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDH wt astrocytoma to glioblastoma

62 structure-based discovery of a series of 5h-pyrrolo[2,3-b]pyrazine fgfr kinase inhibitors

63 sox2 expression is associated with fgfr fusion genes and predicts favorable outcome in lung squamous cell carcinomas

64 y-box protein-1 regulates the expression of collagen i in hepatic progenitor cells via pdgfr-β/erk/p90rsk signalling

65 a high expression egfr/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening egfr antagonists from rhizoma polygoni cuspidati

66 statistical analysis of anthropogenic non-methane voc variability at a european background location (jungfraujoch, switzerland)

67 quantitative analysis of [11c]-erlotinib pet demonstrates specific binding for activating mutations of the egfr kinase domain

68 severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring egfr mutation

69 serum zag levels were associated with egfr mild decrease in t2dm patients with diabetic nephropathy

70 an approach to retrieve information on the carbonyl fluoride (cof<sub>2</sub>) vertical distributions above jungfraujoch by ftir multi-spectrum multi-window fitting

71 synthesis, molecular docking and biological evaluation of glycyrrhizin analogs as anticancer agents targeting egfr

72 tyrosine kinase inhibitors in egfr-mutated large-cell neuroendocrine carcinoma of the lung a case report

73 egfr protein expression using a specific intracellular domain antibody and pten and clinical outcomes in squamous cell lung cancer patients with egfr-tyrosine kinase inhibitor therapy

74 tgf-β and hypoxia/reoxygenation promote radioresistance of a549 lung cancer cells through activation of nrf2 and egfr

75 vascular endothelial growth factor and its soluble receptors vegfr-1 and vegfr-2 in the serum of patients with systemic lupus erythematosus

76 urinary markers of oxidative stress are associated with albuminuria but not gfr decline

77 formyl peptide receptor 1 modulates endothelial cell functions by nadph oxidase-dependent vegfr2 transactivation

78 mir-sc8 inhibits schwann cell proliferation and migration by targeting egfr.

79 spectrum of egfr gene copy number changes and kras gene mutation status in korean triple negative breast cancer patients.

80 chemotherapy and egfr tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients

81 role of the expression level of nrf2 in predicting response of egfr-tkis  in lung adenocarcinoma patients with egfr gene mutations

82 quantum dots immunofluorescence histochemical detection of egfr gene mutations in the non-small cell lung cancers using mutation-specific antibodies

83 reversing egfr mediated immunoescape by targeted monoclonal antibody therapy

84 strengthening of rc slabs with symmetric openings using gfrp composite beams

85 expressions of c-cbl, cbl-b and egfr and its role of prognosis in nsclc

86 siegfried j. schmidt: kalte faszination. medien-kultur-wissenschaft

87 a review of natural joint systems and numerical investigation of bio-inspired gfrp-to-steel joints

88 intercomparison of in situ ndir and column ftir measurements of co<sub>2</sub> at jungfraujoch

89 advancing the manufacture of complex geometry gfrc for today's building envelopes

90 the immune system's contribution to the clinical efficacy of egfr antagonist treatment

91 numerical research on the pullout failure of gfrp bolt

92 the involvement of kras gene 3'-utr polymorphisms in risk of cancer and influence on patient response to anti-egfr therapy in metastatic colorectal cancer: a meta-analysis

93 clinical analysis of icotinib on beneficiary of  advanced non-small cell lung cancer with egfr common mutation

94 académico dr. sigfrido demner 1923 – 2006

95 multiple-response optimization of cutting forces in turning of ud-gfrp composite using distance-based pareto genetic algorithm approach

96 long-term flexural behaviors of gfrp reinforced concrete beams exposed to accelerated aging exposure conditions

97 expression of egfrviii in glioblastoma: prognostic significance revisited

98 folliculin interacts with rab35 to regulate egf-induced egfr degradation

99 experimental study on sandwich bridge decks with gfrp face sheets and a foam-web core loaded under two-way bending

100 egfr-targeted delivery of dox-loaded fe3o4@polydopamine multifunctional nanocomposites for mri and antitumor chemo-photothermal therapy

101 characterization and targeting of platelet-derived growth factor receptor alpha (pdgfra) in inflammatory breast cancer (ibc)

Keyword Connections

Journals

Research Groups

Bibliographies